GlobalData on MSN
Pilatus Biosciences doses first patient in PLT012 antibody trial
The study will assess the tolerability, safety, maximum tolerated dose, and the recommended Phase II dose of PLT012.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results